Regarding EGFr pathway in colorectal cancer, at present, no molecular factors are predictive of response to cetuximab or panitumumab-based treatments except for K-ras mutations (De Roock et al, 2008; Lièvre et al, 2008). This evidence concerns the gene KRAS and colorectal cancer.